araag2/HINT huggingface dataset:
Clinical trial NCT01632007 (phase 3, status: completed)
Conditions: diabetes mellitus
ICD codes: P70.2, O24.92, Z83.3, E10.65, E10.9, E11.65, E11.9
Drugs: syr-472, alogliptin 25 mg, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. The participant is an outpatient.

          2. The participant signs and dates a written, informed consent form and any required
             privacy authorization prior to the initiation of any study procedures.

        Exclusion Criteria:

          1. The participant has any serious cardiac disease, serious cerebrovascular disorder, or
             any serious pancreatic or hematological disease.（e.g., subjects who require
             hospitalization or subjects who were hospitalized within 24 weeks prior to the
             commencement of the observation period)

          2. The participant is considered ineligible for the study for any other reason by the
             investigator or subinvestigator.
Clinical trial NCT01154140 (phase 3, status: completed)
Conditions: non squamous lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: treatment, treatment
SMILES: COC1=CC=CC=C1OC1=C(NS(=O)(=O)C2=CC=C(C=C2)C(C)(C)C)N=C(N=C1OCCO)C1=NC=CC=N1, COC1=CC=CC=C1OC1=C(NS(=O)(=O)C2=CC=C(C=C2)C(C)(C)C)N=C(N=C1OCCO)C1=NC=CC=N1
Eligibility criteria:

        Inclusion Criteria:

          -  Proven diagnosis of locally advanced not suitable for local treatment, recurrent and
             metastatic non-squamous cell carcinoma of the lung

          -  Positive for translocation or inversion events involving the ALK gene locus

          -  No prior systemic treatment for locally advanced or metastatic disease; Patients with
             brain metastases only if treated and neurologically stable with no ongoing requirement
             for corticosteroids

          -  Evidence of a personally signed and dated informed consent document and willingness
             and ability to comply with scheduled visits, treatment plans, laboratory tests, and
             other study procedures including completion of patient reported outcome [PRO]
             measures.

          -  18 years of age or older with the exception of India which has an upper age limit of
             65 years old

        Exclusion Criteria:

          -  Current treatment on another therapeutic clinical trial.

          -  Prior therapy directly targeting ALK.

          -  Any of the following within the 3 months prior to starting study treatment: myocardial
             infarction, severe/unstable angina, coronary/peripheral artery bypass graft,
             congestive heart failure, or cerebrovascular accident including transient ischemic
             attack. - - Appropriate treatment with anticoagulants is permitted.

          -  Ongoing cardiac dysrhythmias of NCI CTCAE Grade >=2, uncontrolled atrial fibrillation
             of any grade, or QTc interval >470 msec.

          -  Pregnancy or breastfeeding.

          -  Use of drugs or foods that are known potent CYP3A4 inducers/inhibitors Concurrent use
             of drugs that are CYP3A4 substrates with narrow therapeutic indices.

          -  Known HIV infection

          -  Known interstitial lung disease or interstitial fibrosis

          -  Other severe acute or chronic medical conditions (including severe gastrointestinal
             conditions such as diarrhea or ulcer) or psychiatric conditions, or laboratory
             abnormalities that would impart, in the judgment of the investigator and/or sponsor,
             excess risk associated with study participation or study drug administration, and
             which would, therefore, make the patient inappropriate for entry into this study
Clinical trial NCT01106625 (phase 3, status: completed)
Conditions: diabetes mellitus, type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: canagliflozin, placebo, metformin, sulphonylruea
SMILES: [H][C@]1(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C1=CC=C(C)C(CC2=CC=C(S2)C2=CC=C(F)C=C2)=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CSCC[C@H](N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  All patients must have a diagnosis of T2DM and be currently treated with metformin and
             sulphonylurea

          -  Patients in the study must have a HbA1c between >=7 and <=10.5%

          -  Patients must have a fasting plasma glucose (FPG) <270 mg/dL (15 mmol/L)

        Exclusion Criteria:

          -  History of diabetic ketoacidosis, type 1 diabetes mellitus (T1DM), pancreas or beta
             cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy, or a
             severe hypoglycemic episode within 6 months before screening
Clinical trial NCT00003857 (phase 3, status: active, not recruiting)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: tamoxifen citrate
SMILES: COC1=CC(NCC2=C(C)C3=C(C=C2)N=C(N)N=C3N)=CC(OC)=C1OC
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Ductal carcinoma in situ (DCIS) of the breast detected by mammogram at the time of
             diagnosis

               -  Unicentric

               -  Lesions ≤ 2.5 cm

               -  Low nuclei grade (NG1) or intermediate nuclei grade (NG2) with necrosis in < one
                  third of the involved ducts

               -  Inked margins ≥ 3 mm

               -  Clinically node negative

               -  Non-palpable

          -  No suspicious areas on post-operative mammogram taken within 12 weeks after final
             surgery

          -  No bloody nipple discharge

          -  No more than 12 weeks since prior final surgery (arm II only)

          -  Hormone receptor status:

               -  Not specified

        PATIENT CHARACTERISTICS:

        Age:

          -  26 and over

        Sex:

          -  Female

        Menopausal status:

          -  Not specified

        Performance status:

          -  Not specified

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Not specified

        Hepatic:

          -  Not specified

        Renal:

          -  Not specified

        Other:

          -  Not pregnant or nursing

          -  No active connective tissue disorders (e.g., lupus or scleroderma)

          -  No prior malignancy within the past 5 years except adequately treated basal cell or
             squamous cell skin cancer or carcinoma in situ of the cervix

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  No prior chemotherapy

        Endocrine therapy:

          -  No other concurrent hormonal therapy (e.g., raloxifene, hormone replacement therapy,
             or birth control pills)

        Radiotherapy:

          -  No prior radiotherapy

        Surgery:

          -  See Disease Characteristics
Clinical trial NCT00351507 (phase 3, status: completed)
Conditions: diabetes mellitus, type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: vildagliptin
SMILES: CN(C)C(=N)NC(N)=N
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosed with type 2 diabetes for at least 6 months

          -  Blood glucose criteria must be met

          -  BMI in the range 22-40

        Exclusion Criteria:

          -  History of type 1 diabetes, diabetes resulting from pancreatic injury, or secondary
             forms of diabetes

          -  Use of thiazolidinediones or need for insulin within 3 months prior to screening

          -  Significant concomitant diseases or complications of diabetes

          -  High fasting triglycerides as defined by the protocol

        Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT01035346 (phase 3, status: terminated)
Conditions: infection
ICD codes: K94.02, K94.12, K94.22, K94.32, N99.511, A02.9, A31.0
Drugs: ibuprofen, placebo
SMILES: CC1=CC(O)=CC(C)=C1Cl, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects diagnosed with a fever secondary to an uncomplicated acute viral or bacterial
             infection.

          -  Oral temperature measurement from 100 to 104 degrees Fahrenheit.

          -  Onset of fever 3 days or less.

          -  Otherwise good health.

        Exclusion Criteria:

          -  Fever secondary to a chronic underlying medical condition or serious infection.

          -  Currently taking antibiotics or antivirals.

          -  Currently taking any medication which may interfere with the assessment of fever.

          -  Pregnancy or breast-feeding.

          -  Any serious medical or psychiatric disorder.
Clinical trial NCT00667719 (phase 3, status: completed)
Conditions: essential hypertension
ICD codes: I10, O10.02, O10.03, O10.011, O10.012, O10.013, O10.019
Drugs: aliskiren /amlodipine/hydrochlorothiazide
SMILES: NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Outpatients 18 years of age or older

          -  Male or female patients are eligible.

          -  msDBP & msSBP Requirements:

               -  For newly diagnosed/untreated patients, msDBP ≥ 100 and < 120 mmHg, and/or msSBP
                  ≥ 160 and < 200 mmHg at Visit 1 and Visit 2.

               -  For previously treated patients, msDBP ≥ 100 and < 120 mmHg, and/or msSBP ≥ 160
                  and < 200 mmHg at Visit 2, Visit 3, or Visit 4.

          -  For patients requiring tapering off their previous antihypertensive medication, they
             must meet the above criteria and completely discontinue all antihypertensive treatment
             prior to entering the treatment phase of the study.

          -  Patients who are eligible and able to participate in the study, and who consent to do
             so after the purpose and nature of the investigation has been clearly explained to
             them (written informed consent).

        Exclusion Criteria:

          -  Inability to discontinue all prior antihypertensive medications safely for a period of
             1 week to 4 weeks as required by the protocol.

          -  Patients on three antihypertensive drugs with msDBP ≥ 110 mmHg and/or msSBP ≥ 180 mmHg
             at Visit 1.

          -  Patients on four or more antihypertensive drugs at Visit 1.

          -  Patients with an msSBP ≥ 200 and msDBP ≥ 120 mmHg anytime during the washout period of
             the study Visit 1-4 must be discontinued from the study.

          -  Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a
             female after conception and until the termination of gestation, confirmed by a
             positive hCG laboratory test (>= 5 mIU/mL).
Clinical trial NCT00533897 (phase 3, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: abatacept, placebo
SMILES: [H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Clinical diagnosis of Rheumatoid Arthritis

          -  Disease Activity Score (DAS)28-C-Reactive Protein (CRP) score ≥ 3.2 and ≤5.1

          -  On background methotrexate at least 3 months (≥10mg weekly)

          -  Must be able to self injection or allow a care giver to do it for them

          -  Discontinue all Biologics and Disease-Modifying Anti-rheumatic Drugs (DMARDs) except
             for methotrexate

        Exclusion Criteria:

          -  Participants who had prior exposure to abatacept or CTLA-4 Ig

          -  Received treatment with rituximab.

          -  Participants who have received treatment with leflunomide within 1 year of screening

          -  Participants who have received treatment with immunoadsorption columns (such as
             Prosorba columns), mycophenolate mofetil (Cellcept®), cyclosporine A or other
             calcineurin inhibitors, or D-Penicillamine.
Clinical trial NCT00255086 (phase 3, status: completed)
Conditions: alzheimer disease
ICD codes: G30.8, G30.9, G30.0, G30.1
Drugs: memantine, placebo pill
SMILES: CC12CC3CC(C)(C1)CC(N)(C3)C2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:1. Dementia criteria by DSM-IV.

        2. 50-95 years of age inclusive.

        3. MMSE at screen and baseline 7-28 inclusive.

        4. Conversant in English.

        5. Caregiver/study partner willing to participate, supervise the patient and be available
        for administration of study medication.

        6. Able to ingest oral medication. Exclusion Criteria:1. History of clinically significant
        stroke without substantial recovery.

        2. Neurological or medical conditions causing significant disability independent of
        dementia.

        3. Parkinson's disease.

        4. History in past two years of focal brain lesion, head injury with loss of consciousness
        or DSM-IV criteria for any major psychiatric disorder including psychosis, major
        depression, bipolar disorder, alcohol or substance abuse.

        5. Dementia due to Korsakoff's syndrome or infectious diseases such as Creutzfeldt-Jakob
        disease, herpes, encephalitis, or human immunodeficiency virus.

        6. Sensory impairment that would prevent subject from participating in or cooperating with
        the protocol.

        7. Significant clinical disorder or laboratory finding that renders the subject unsuitable
        for receiving an investigational drug including: clinically significant or unstable
        hematologic, hepatic, cardiovascular, pulmonary, gastrointestinal, endocrine, metabolic,
        renal, or other systemic disease or laboratory abnormality.

        8. Clinical contraindication to the use of memantine (e.g., hypersensitivity).

        9. History of seizure within past 5 years prior to screening.

        10. Platelet count < 100,000/mm3.

        11. History of claustrophobia

        12. Presence of metallic implants such as pacemakers, surgical aneurysm clips, or known
        metal fragments embedded in the body
Clinical trial NCT02686619 (phase 3, status: completed)
Conditions: renal transplantation
ICD codes: N25.0, Q61.4, N23, N26.9, P96.0, Q60.0, Q60.1
Drugs: cyclosporine, daclizumab, mycophenoate mofetil, prednisolone, sirolimus
SMILES: CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, COC1=C(C\C=C(/C)CCC(=O)OCCN2CCOCC2)C(O)=C2C(=O)OCC2=C1C, [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, CC(=O)CC(C1=CC=CC=C1)C1=C(O)C2=C(OC1=O)C=CC=C2
Eligibility criteria:

        Inclusion Criteria:

          -  Receipt of a first cadaveric kidney graft

          -  Antilymphocyte antibodies and panel reactive antibodies (PRA) less than 30 percent (%)
             (historical peak and/or current value)

          -  Cold ischaemia time less than or equal to 36 hours

        Exclusion Criteria:

          -  Kidney from a living donor; donor greater than (>) 65 years of age; second renal
             graft, or more; or multiple organ transplant

          -  Known hypersensitivity to any of the drugs in the study or their components

          -  History of cancer or malignancy during previous 5 years, other than successfully
             treated spinocellular or basal cell cancer

          -  Participant presenting, on inclusion, either symptoms suggestive of active
             gastroduodenal ulcer, or gastroduodenal ulcer confirmed by fibroscopy and biopsy, and
             requiring treatment

          -  Participant with severe refractory hyperlipidaemia

          -  Pregnant woman or nursing mother

        Exclusion Criteria for Follow-up Phase:

          -  Episode of acute rejection greater than or equal to grade I (Banff classification)

          -  Estimated creatinine clearance (CrCl) at week 12 less than (<) 40 milliliter per
             minute (mL/min) (Cockcroft-Gault formula)

          -  Serum creatinine variations >30% during the 15 days before randomization

          -  Proteinuria >1 gram/24 hour, or mean mycophenolate mofetil dose < 1.5 gram/day during
             the week before randomization
Clinical trial NCT00578786 (phase 3, status: completed)
Conditions: pulmonary arterial hypertension
ICD codes: I27.21
Drugs: ambrisentan
SMILES: COC([C@H](OC1=NC(C)=CC(C)=N1)C(O)=O)(C1=CC=CC=C1)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          1. Subject must have completed Week 12 of AMB-320 (NCT00423748) or AMB-321 (NCT00423202)
             or must have received placebo during AMB-320 (NCT00423748) or AMB-321 (NCT00423202)
             and met two or more early escape criteria;

          2. Subject must be competent to understand the information given in the Institutional
             Review Board (IRB) or Independent Ethics Committee (IEC) approved informed consent
             form and must sign the form prior to the initiation of any study procedures.

          3. Female subject of childbearing potential must agree to use two reliable methods of
             contraception until study completion and for at least four weeks following their final
             study visit. Reliable methods include: birth control pills/implants/injections,
             intrauterine devices (IUDs), spermicide, diaphragms, or condoms.

        Exclusion Criteria:

          -  Subjects must have met the exclusion criteria of the AMB-320 (NCT00423748) and AMB-321
             (NCT00423202)studies. In addition, a subject who meets any one of the following
             criteria is ineligible for participation in the study:

               1. Subject receiving bosentan, sildenafil, or iv inotropes at any time within four
                  weeks prior to the AMB-320/321-E Screening/Randomization Visit;

               2. Subject receiving chronic prostanoid therapy (epoprostenol, treprostinil,
                  iloprost, beraprost, or any other investigational prostacyclin derivative) within
                  four weeks prior to the AMB-320/321-E Screening/RandomizationVisit;

               3. Female subject who is pregnant or breastfeeding;

               4. Subject with cardiovascular, liver, renal, hematologic, gastrointestinal,
                  immunologic, endocrine, metabolic, or central nervous system disease that, in the
                  opinion of the Investigator, may adversely affect the safety of the subject
                  and/or efficacy of the study drug or severely limit the lifespan of the subject;

               5. Subject who has demonstrated noncompliance with previous medical regimens;

               6. Subject who has a recent history of abusing alcohol or illicit drugs;

               7. Subject who has participated in a clinical study involving another
                  investigational drug or device at any time within four weeks prior to the
                  AMB-320/321-E Screening/Randomization Visit.
Clinical trial NCT01594346 (phase 3, status: completed)
Conditions: alzheimer's disease, down syndrome
ICD codes: G30.8, G30.9, G30.0, G30.1, Q90.9
Drugs: alpha-tocopherol, sugar pill
SMILES: CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@]1(C)CCC2=C(O1)C(C)=C(C)C(O)=C2C, OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O
Eligibility criteria:

        Inclusion Criteria:

          -  presence of clinically determined Down syndrome (karyotypes optional)

          -  appropriately signed and witnessed consent form

          -  age of 50 years or older at the start of the protocol

          -  medically stable

          -  medications stable more than 1 month

          -  involvement/cooperation of informant/caregiver

        Exclusion Criteria:

          -  medical/neurological condition (other than Alzheimer disease) associated with dementia

          -  inability to adequately perform the Brief Praxis Test, as demonstrated by a score <20

          -  in the presence of dementia, modified Hachinski score > 4 at Screening Visit

          -  major depression within 3 months

          -  history of coagulopathy (inherited or acquired)

          -  current use of anticoagulants

          -  use of experimental medications within 2 months

          -  regular use of vitamin E greater than 50 units per day during the previous 6 months

          -  allergy to vitamin E
Clinical trial NCT00431132 (phase 3, status: completed)
Conditions: menopause, postmenopausal vaginal atrophy
ICD codes: E28.310, E28.319
Drugs: estradiol, 10 mcg
SMILES: [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
Eligibility criteria:

        Inclusion Criteria:

          -  Postmenopausal women whose last menstruation was at least two years prior to the time
             of screening

          -  At least 1 urogenital symptom (vaginal dryness, vaginal and/or vulvar
             irritation/itching, vaginal soreness, dysuria, dyspareunia and vaginal bleeding
             associated with sexual activity

          -  Generally healthy

        Exclusion Criteria:

          -  Exposure to exogenous sex steroid hormones (estrogen and/or progestin hormone
             replacement therapy) within past 3 months
Clinical trial NCT00163111 (phase 3, status: completed)
Conditions: candidiasis
ICD codes: B37.1, B37.9, P37.5, B37.49, B37.89, B37.2, B37.3
Drugs: vfendâ® i.v., oral, conventional amphotericin b, diflucan iv, oral
SMILES: [H][C@]12SCC(CSC3=NN=C(C)S3)=C(N1C(=O)[C@H]2NC(=O)CN1C=NN=N1)C(O)=O, OC(CN1C=NC=N1)(CN1C=NC=N1)C1=C(F)C=C(F)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with candidemia

        Exclusion Criteria:

          -  Neutropenia
Clinical trial NCT01232894 (phase 3, status: completed)
Conditions: chronic obstructive pulmonary disease (copd)
ICD codes: G91.1, I42.1, N11.1, J05.0, G47.33, J44.9, N13.8
Drugs: indacaterol, long-acting beta2-agonist
SMILES: CCC1=C(CC)C=C2CC(CC2=C1)NC[C@H](O)C1=C2C=CC(=O)NC2=C(O)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of Chronic Obstructive Pulmonary Disease (COPD) (moderate-to-severe as
             classified by the Global Initiative for Chronic Obstructive Lung Disease (GOLD)
             Guidelines, 2007) and:

          -  Post-bronchodilator forced expiratory volume in 1 second (FEV1) <80% and ≥30% of the
             predicted normal value

          -  Post-bronchodilator FEV1/FVC (Forced Vital Capacity) <70%

          -  Current COPD bronchodilator treatment that includes a LABA bronchodilator or a fixed
             dose combination of LABA and Inhaled Corticosteroid (ICS)

        Exclusion Criteria:

          -  Patients with a history of asthma

          -  Patients who are currently being treated for COPD with tiotropium (Spiriva®)

          -  Patients with diabetes Type I or uncontrolled diabetes Type II

          -  Patients with a history of certain cardiovascular comorbid conditions

        Other protocol-defined inclusion/exclusion criteria may apply